Adenoviral gene transfer corrects the ion transport defect in the sinus epithelia of a porcine CF model

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 947-953

  Potash, Andrea E ^a   Wallen, Tanner J ^a   Karp, Philip H ^a   Ernst, Sarah ^a   Moninger, Thomas O ^a   Gansemer, Nicholas D ^a   Stoltz, David A ^a   Zabner, Joseph ^a   Chang, Eugene H ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANION TRANSPORT; CFTR GENE; CONFERENCE PAPER; CONTROLLED STUDY; CYSTIC FIBROSIS; ION CURRENT; ION TRANSPORT; NEWBORN; NONHUMAN; PARANASAL SINUS; PROTEIN EXPRESSION; SINUS EPITHELIA; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; SUIDAE; SUS;

EID: 84877079632     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.49     Document Type: Conference Paper

References (50)

1. Ledesma-Medina, J, Osman, MZ and Girdany, BR (1980). Abnormal paranasal sinuses in patients with cystic fibrosis of the pancreas. Radiological findings. Pediatr Radiol 9: 61-64.
2. Riordan, JR, Rommens, JM, Kerem, B, Alon, N, Rozmahel, R, Grzelczak, Z et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
3. Welsh, MJ, Ramsey, BW, Accurso, F and Cutting, GR (2001). Cystic fibrosis. In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, Childs, B and Vogelstein, B (eds). The Metabolic and Molecular Basis of Inherited Disease, 8th edn. McGraw-Hill: New York. pp. 5121-5189.
4. Wine, JJ, King, VV and Lewiston, NJ (1991). Method for rapid evaluation of topically applied agents to cystic fibrosis airways. Am J Physiol 261(2 Pt 1): L218-L221.
5. Wagner, JA, Moran, ML, Messner, AH, Daifuku, R, Conrad, CK, Reynolds, T et al. (1998). A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 9: 889-909.
6. Wagner, JA, Nepomuceno, IB, Messner, AH, Moran, ML, Batson, EP, Dimiceli, S et al. (2002). A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 13: 1349-1359.
7. Chang, EH, Pezzulo, AA, Meyerholz, DK, Potash, AE, Wallen, TJ, Reznikov, LR et al. (2012). Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. Laryngoscope 122: 1898-1905.
8. Boucher, RC (2007). Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261: 5-16.
9. Davis, PB (2006). Cystic fibrosis since 1938. Am J Respir Crit Care Med 173: 475-482.
10. Quinton, PM (1999). Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 79(1 Suppl): S3-S22.
11. Rowe, SM, Miller, S and Sorscher, EJ (2005). Cystic fibrosis. N Engl J Med 352: 1992-2001.
12. Verkman, AS, Song, Y and Thiagarajah, JR (2003). Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol, Cell Physiol 284: C2-15.
13. Wine, JJ (1999). The genesis of cystic fibrosis lung disease. J Clin Invest 103: 309-312.
14. Karp, PH, et al. (2002). An in vitro model of differentiated human airway epithelia: methods and evaluation of primary cultures. In: Wise, C (ed). Epithelial Cell Culture Protocols, vol. 188. Humana Press, Inc.: Totowa. pp. 115-137.
15. Muanprasat, C, Sonawane, ND, Salinas, D, Taddei, A, Galietta, LJ and Verkman, AS (2004). Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 124: 125-137.
16. Chen, JH, Stoltz, DA, Karp, PH, Ernst, SE, Pezzulo, AA, Moninger, TO et al. (2010). Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143: 911-923.
17. Knowles, M, Gatzy, J and Boucher, R (1981). Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305: 1489-1495.
18. Standaert, TA, Boitano, L, Emerson, J, Milgram, LJ, Konstan, MW, Hunter, J et al. (2004). Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 37: 385-392.
19. Granio, O, Norez, C, Ashbourne Excoffon, KJ, Karp, PH, Lusky, M, Becq, F et al. (2007). Cellular localization and activity of Ad-delivered GFP-CFTR in airway epithelial and tracheal cells. Am J Respir Cell Mol Biol 37: 631-639.
20. Farmen, SL, Karp, PH, Ng, P, Palmer, DJ, Koehler, DR, Hu, J et al. (2005). Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl-transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 289: L1123-L1130.
21. Excoffon, KJ, Koerber, JT, Dickey, DD, Murtha, M, Keshavjee, S, Kaspar, BK et al. (2009). Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci USA 106: 3865-3870.
22. Wang, X, Kim, J, McWilliams, R and Cutting, GR (2005). Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch Otolaryngol Head Neck Surg 131: 237-240.
23. Wang, X, Moylan, B, Leopold, DA, Kim, J, Rubenstein, RC, Togias, A et al. (2000). Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284: 1814-1819.
24. Harvey, BG, Leopold, PL, Hackett, NR, Grasso, TM, Williams, PM, Tucker, AL et al. (1999). Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 104: 1245-1255.
25. Hyde, SC, Southern, KW, Gileadi, U, Fitzjohn, EM, Mofford, KA, Waddell, BE et al. (2000). Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7: 1156-1165.
26. Knowles, MR, Paradiso, AM and Boucher, RC (1995). In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6: 445-455.
27. Porteous, DJ, Dorin, JR, McLachlan, G, Davidson-Smith, H, Davidson, H, Stevenson, BJ et al. (1997). Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 4: 210-218.
28. Wagner, JA, Messner, AH, Moran, ML, Daifuku, R, Kouyama, K, Desch, JK et al. (1999). Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109(2 Pt 1): 266-274.
29. Zabner, J, Wadsworth, SC, Smith, AE and Welsh, MJ (1996). Adenovirusmediated generation of cAMP-stimulated Cl-transport in cystic fibrosis airway epithelia in vitro: effect of promoter and administration method. Gene Ther 3: 458-465.
30. Zuckerman, JB, Robinson, CB, McCoy, KS, Shell, R, Sferra, TJ, Chirmule, N et al. (1999). A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 10: 2973-2985.
31. Alton, EW, Stern, M, Farley, R, Jaffe, A, Chadwick, SL, Phillips, J et al. (1999). Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353: 947-954.
32. Gill, DR, Southern, KW, Mofford, KA, Seddon, T, Huang, L, Sorgi, F et al. (1997). A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 4: 199-209.
33. Joseph, PM, O'Sullivan, BP, Lapey, A, Dorkin, H, Oren, J, Balfour, R et al. (2001). Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther 12: 1369-1382.
34. Moss, RB, Milla, C, Colombo, J, Accurso, F, Zeitlin, PL, Clancy, JP et al. (2007). Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebocontrolled phase 2B trial. Hum Gene Ther 18: 726-732.
35. Moss, RB, Rodman, D, Spencer, LT, Aitken, ML, Zeitlin, PL, Waltz, D et al. (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125: 509-521.
36. Harvey, BG, Leopold, PL, Hackett, NR, Grasso, TM, Williams, PM, Tucker, AL et al. (1999). Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 104: 1245-1255.
37. Wagner, JA, Reynolds, T, Moran, ML, Moss, RB, Wine, JJ, Flotte, TR et al. (1998). Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351: 1702-1703.
38. Zabner, J, Petersen, DM, Puga, AP, Graham, SM, Couture, LA, Keyes, LD et al. (1994). Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 6: 75-83.
39. Zabner, J, Ramsey, BW, Meeker, DP, Aitken, ML, Balfour, RP, Gibson, RL et al. (1996). Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 97: 1504-1511.
40. Starner, TD and McCray, PB Jr; American College of Physicians; American Physiological Society (2005). Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 143: 816-822.
41. Johnson, LG, Olsen, JC, Sarkadi, B, Moore, KL, Swanstrom, R and Boucher, RC (1992). Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2: 21-25.
42. Zhang, L, Button, B, Gabriel, SE, Burkett, S, Yan, Y, Skiadopoulos, MH et al. (2009). CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 7: e1000155.
43. Oakland, M, Sinn, PL and McCray, PB Jr (2012). Advances in cell and gene-based therapies for cystic fibrosis lung disease. Mol Ther 20: 1108-1115.
44. Burnight, ER, Wang, G, McCray, PB Jr and Sinn, PL (2012). Transcriptional targeting in the airway using novel gene regulatory elements. Am J Respir Cell Mol Biol 47: 227-233.
45. Mitomo, K, Griesenbach, U, Inoue, M, Somerton, L, Meng, C, Akiba, E et al. (2010). Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 18: 1173-1182.
46. Ostedgaard, LS, Meyerholz, DK, Vermeer, DW, Karp, PH, Schneider, L, Sigmund, CD et al. (2011). Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/-mice. Proc Natl Acad Sci USA 108: 2921-2926.
47. Sinn, PL, Cooney, AL, Oakland, M, Dylla, DE, Wallen, TJ, Pezzulo, AA et al. (2012). Lentiviral vector gene transfer to porcine airways. Mol Ther Nucleic Acids 1: e56.
48. Stocker, AG, Kremer, KL, Koldej, R, Miller, DS, Anson, DS and Parsons, DW (2009). Single-dose lentiviral gene transfer for lifetime airway gene expression. J Gene Med 11: 861-867.
49. Rogers, CS, Hao, Y, Rokhlina, T, Samuel, M, Stoltz, DA, Li, Y et al. (2008). Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virusmediated gene targeting and somatic cell nuclear transfer. J Clin Invest 118: 1571-1577.
50. Rogers, CS, Stoltz, DA, Meyerholz, DK, Ostedgaard, LS, Rokhlina, T, Taft, PJ et al. (2008). Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321: 1837-1841.